ReviewSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2026
Exploring the pivotal role of hot melt extrusion technology in developing PLGA based novel drug delivery platforms for better therapeutic outcomes.
Review in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Among various biodegradable polymers, polylactic-co-glycolic acid (PLGA) is one of most widely studied synthetic polymer for controlled and targeted drug delivery. PLGA is a smart polymer as it has stimuli-responsive behaviour. PLGA is approved by the US FDA for multiple therapeutic applications due to its biodegradability, biocompatibility and sustained-release behaviour. PLGA is commercially available as different molecular weights and copolymer ratios, which allow for tuning polymer behaviour to suit numerous applications. Different methods have been used to process PLGA into diverse morphologies, structures and sizes. Traditional PLGA processing methods face many limitations related to scalability and residual solvents. This review was limited to the emerging hot melt extrusion (HME), a more specific, solvent-free and highly scalable technology for fabricating PLGA-based formulations. Key operational parameters such as glass transition temperature, melt viscosity, and degradation behaviour are discussed alongside with the drug-related stability, dispersion and final solid-state properties that need several factors to be fine-tuned to offer a performance with optimal efficiency. This tunability of characteristics makes PLGA driven by HME ideal for fabrication with advanced manufacturing technologies to deliver surprisingly novel drug delivery platforms that can boost therapeutic efficacy and patient compliance across a range of clinical fields.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.